

Lindsey E Roeker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4218236/publications.pdf>

Version: 2024-02-01

37
papers

1,594
citations

516710

16
h-index

395702

33
g-index

37
all docs

37
docs citations

37
times ranked

2355
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2022, 386, 735-743. | 27.0 | 87 |
| 2 | Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy. <i>Drugs</i> , 2022, 82, 133-143. | 10.9 | 6 |
| 3 | The potential of pirtobrutinib in multiple B-cell malignancies. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211016. | 2.5 | 12 |
| 4 | Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557. | 5.2 | 22 |
| 5 | Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K γ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826. | 1.4 | 38 |
| 6 | Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901. | 13.7 | 260 |
| 7 | COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 2703-2705. | 7.2 | 126 |
| 8 | Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. <i>Leukemia and Lymphoma</i> , 2021, 62, 1940-1948. | 1.3 | 7 |
| 9 | Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice. <i>British Journal of Haematology</i> , 2021, 194, 9-10. | 2.5 | 3 |
| 10 | Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. <i>Blood Advances</i> , 2021, 5, 2879-2889. | 5.2 | 16 |
| 11 | COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773. | 1.4 | 53 |
| 12 | Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021, 2, 568-576. | 5.0 | 62 |
| 13 | Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 529-539. | 2.0 | 14 |
| 14 | Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143. | 1.4 | 248 |
| 15 | Approaches for relapsed CLL after chemotherapy-free frontline regimens. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 10-17. | 2.5 | 8 |
| 16 | Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. <i>A GIMEMA-ERIC and US study</i> . <i>Cancer Medicine</i> , 2020, 9, 8468-8479. | 2.8 | 12 |
| 17 | <p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020, Volume 10, 1-5. | 2.7 | 1 |
| 18 | Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989. | 5.2 | 55 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 3047-3049. | 7.2 | 81 |
| 20 | Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596. | 7.0 | 80 |
| 21 | Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. <i>Blood</i> , 2020, 136, 39-41. | 1.4 | 13 |
| 22 | Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE). <i>Blood</i> , 2020, 136, 19-22. | 1.4 | 0 |
| 23 | Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144. | 2.0 | 36 |
| 24 | A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573. | 5.2 | 26 |
| 25 | Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia. <i>JAMA Network Open</i> , 2019, 2, e1916326. | 5.9 | 22 |
| 26 | Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116. | 6.2 | 64 |
| 27 | Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e421-e426. | 0.4 | 9 |
| 28 | Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 1394-1401. | 4.1 | 52 |
| 29 | Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517. | 3.5 | 135 |
| 30 | Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. <i>Blood</i> , 2015, 126, 1401-1401. | 1.4 | 0 |
| 31 | Imatinib-associated melanosis of the palate. <i>American Journal of Hematology</i> , 2014, 89, 564-564. | 4.1 | 14 |
| 32 | Self-perceptions of age among 292 chemotherapy-treated cancer patients: Exploring associations with symptoms and survival. <i>Journal of Geriatric Oncology</i> , 2013, 4, 249-254. | 1.0 | 6 |
| 33 | Cyclic Bicytopenia in a Patient with Shapiro Syndrome. <i>Case Reports in Hematology</i> , 2013, 2013, 1-4. | 0.4 | 8 |
| 34 | Development Of Solid Malignancies In Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS): A Population-Based Study Of 17,315 Patients. <i>Blood</i> , 2013, 122, 3134-3134. | 1.4 | 0 |
| 35 | Pruritus in primary myelofibrosis: Clinical and laboratory correlates. <i>American Journal of Hematology</i> , 2012, 87, 136-138. | 4.1 | 12 |
| 36 | Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. <i>Blood</i> , 2012, 120, 3555-3555. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. <i>Blood</i> , 2012, 120, 934-934. | 1.4 | 0 |